Eye drugs list: Sodium hyaluronate, tafluprost, tobramycin uses

Eye Drugs List: Sodium Hyaluronate, Tafluprost, Tobramycin Uses

Pharma professionals tracking ophthalmic therapeutics need a grounded reference on current treatment options. This plan organizes a tightly sourced eye drugs list around dry eyes, glaucoma, and eye infections. It keeps the focus on what the evidence confirms and avoids unsupported market or investment claims.

IntelligenceRegulatory Impact▾

FDA decisions frame this story. Regulatory relevance is high for dry eyes, with Sodium cromoglicate and Sodium hyaluronate most exposed. Track designations, submission types, and label or guidance shifts that could move timelines.

What the Evidence Confirms

Sodium hyaluronate is used for the treatment of dry eyes, while tafluprost eye drops are used for glaucoma treatment. For bacterial infections, tobramycin is used to treat eye infections. These topical formulations represent the most common first-line pharmacologic approaches in primary eye care.

Beyond drops, eye doctors sometimes use injections to treat certain eye conditions. These injections can be anti-VEGF drugs or steroids, according to the National Eye Institute. This injection-based approach extends treatment options for conditions where topical delivery alone may be insufficient.

From an FDA regulatory standpoint, sodium hyaluronate carries FDA labeling as a topical formulation with the generic name CARBON, PANTHENOL, SODIUM HYALURONATE, manufactured by WU XI ZHONG ZHI WEI NA TECHNOLOGY CO., Ltd. The agency's labeling reflects current approved uses, though the scope of clinical development continues to evolve across multiple indication areas.

IntelligenceCompetitive Intelligence▾

Eli Lilly, NewLimit, and Allergan are directly implicated. Competitive pressure reads medium — compare pipeline positioning and partnership scouting against signals in this story.

Clinical Development Activity

Sodium cromoglicate, a related stabilizer compound, is under active investigation in multiple therapeutic contexts. A Phase 2 trial (NCT07142291) is recruiting patients with mild to moderate amyotrophic lateral sclerosis (ALS) to evaluate cromolyn treatment, sponsored by PhenoNet, Inc. In parallel, a Phase 1/2 trial (NCT03794076) is recruiting to assess cromoglicate as adjunctive therapy for outpatients with schizophrenia and schizoaffective disorder, led by Vishwajit Nimgaonkar, MD PhD.

Two additional Phase 2 trials remain in earlier recruitment stages: a mast cell stabilizer study (NCT07526558) for post-tick bite illness, sponsored by the University of North Carolina, Chapel Hill, has not yet begun recruiting, and an immunotherapy re-challenge study (NCT07419880) for immune-refractory triple-negative breast cancer, sponsored by Fudan University, is also not yet recruiting.

IntelligenceMarket Signals▾

Commercial pull is high and investment relevance high for dry eyes. Expect implications for pricing, access, and launch sequencing.

Key Takeaways

• Sodium hyaluronate, tafluprost, and tobramycin represent the current standard topical options for dry eyes, glaucoma, and eye infections, respectively, as confirmed by evidence-based clinical references.
• Anti-VEGF and steroid injections extend the treatment armamentarium for certain eye conditions beyond topical delivery, per National Eye Institute guidance.
• Sodium cromoglicate derivatives are advancing through Phase 1/2 and Phase 2 trials in non-ophthalmologic indications including ALS, schizophrenia, and oncology, signaling continued clinical interest in the mast cell stabilizer class.
• FDA regulatory oversight confirms topical sodium hyaluronate formulations are approved and manufactured under current good manufacturing practice standards.

Frequently Asked Questions